Irinotecan and Temozolamide Treatment for Relapsed Ewing Sarcoma: A Single-Center Experience and Review of the Literature

REFERENCES

• Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist. 2006;11:503–519
   PubMed Web of Science ®Google Scholar
• Subbiah V, Anderson P, Lazar AJ, et al. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Opt Oncol. 2009;10:126–140
   Google Scholar
• Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 2011;57:549–553
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: The St. Jude Children's Research Hospital experience, 1979–1999. Cancer. 2002;94:561–569
   PubMed Web of Science ®Google Scholar
• Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs. 2008;17:1703–1715
   PubMed Web of Science ®Google Scholar
• Wagner LM, McAllister N, Robert E, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48:132–139
   PubMed Web of Science ®Google Scholar
• Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2009;53:1029–1034
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247
   PubMed Web of Science ®Google Scholar
• Wexler LH, DeLaney TF, Tsokos M. lfosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 1996;78: 901–911
   PubMed Web of Science ®Google Scholar
• Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26:4385–4393
   PubMed Web of Science ®Google Scholar
• Kalambakas SA, Moore TB, Feig SA. Megatherapy and stem cell transplantation for Ewing's family of tumors: a critical review of current literature. Pediatr Transplant. 2004;(Suppl-5):83–88
   Google Scholar
• Subbiah V, Kurzrock R. Ewing sarcoma: Overcoming the therapeutic plateau. Discov Med. 2012;13:405–415
   Google Scholar
• Ferrari S, Del Prever AB, Palmerini E, et al. Response to high dose ifosfamide in patients with advanced/recurrent Ewing's tumors. Pediatr Blood Cancer. 2009;52 581–584.
   PubMed Web of Science ®Google Scholar
• Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005;44:338–347
   PubMed Web of Science ®Google Scholar
• Farhat R, Raad R, Khoury NJ, et al. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution. J Pediatr Hematol Oncol. 2013;35:356–360
   PubMed Web of Science ®Google Scholar
• Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012;17: 321–329
   PubMed Web of Science ®Google Scholar
• Wagner L. Camptothecin-based regimens for treatment of Ewing sarcoma: past studies and future drections. Sarcoma 2011; 2011:957957. doi: 10.1155/2011/957957
   Google Scholar
• Houghton PJ, Cheshire PJ, Halman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393–403
   PubMed Web of Science ®Google Scholar
• Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999;17:1815–1824
   PubMed Web of Science ®Google Scholar
• Tatar Z, Thivat E, Planchat E, et al. Temozolomide and unusual indications: review of literature. Cancer Treat Rev. 2013;39:125–135
   PubMed Web of Science ®Google Scholar
• Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007; 25:362–369.
   PubMedGoogle Scholar
• Wagner LM, Crews KR, Iacono LC, et al. Phase I Trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res. 2004;10:840–848
   PubMed Web of Science ®Google Scholar
• McNall-Knapp RY, Williams CN, Reeves EN, et al. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors Pediatr Blood Cancer. 2010;54:909–915
   PubMed Web of Science ®Google Scholar
• Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with relapse or progression of rhabdomysarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2010;28:4656–4663.
   Google Scholar
• Wagner LM. Oral irinotecan for treatment of pediatric solid tumors: ready for prime time. Pediatr Blood Cancer. 2010;54:661–662.
   Google Scholar
• Wagner LM, Perentesis JP, Reid JM, et al. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolamide (VOIT) for children with relapsed or refractory solid tumors: A children's Oncology Group Phase I Consortium Study. Pediatr Blood Cancer. 2010;54:538–545
   PubMed Web of Science ®Google Scholar
• Wagner L, Turpin B, Nagarajan R, et al. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr Blood Cancer. 2013;60:1447–51.
   PubMed Web of Science ®Google Scholar
• Raciborska A, Bilska K, Drabko K, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013;60:1621–1625.
   PubMed Web of Science ®Google Scholar
• Wagner LM, Crews KR, Stewart CF, et al. Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer 2008;50:201–207
   Google Scholar
• Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol. 2006;24:563–570
   PubMed Web of Science ®Google Scholar